Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the proprietary aptamer TAGX-0003 significantly inhibited IFNγ-induced effects in pre-clinical human models of alopecia areata, promoting hair regrowth and potentially preventing disease relapse.

This study established an IRGDS model with diagnostic capability for alopecia areata, which may serve as an auxiliary marker for the condition.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

This study found that in Arabidopsis, root hair-specific proteins ADF8 and ADF11 are crucial for responding to hormonal signals like auxin and ethylene, which in turn modulate actin filament dynamics and are key for root hair growth under various environmental conditions.

This case report describes the diagnosis and management of a 15-year-old girl with complete androgen insensitivity syndrome, highlighting the importance of thorough physical exams for early detection and treatment planning.

This study utilized computational approaches to screen natural compounds targeting a non-androgen pathway involving PIEZO1 and MLCK for treating androgenetic alopecia, identifying several potential candidates for further validation but making no clinical claims.

This study found that Ifidancitinib, a JAK1/3 inhibitor, significantly promoted hair regrowth and reduced inflammation in a mouse model of alopecia areata by decreasing pathogenic T cell activity and inducing T cell exhaustion.

This review discusses the clinical efficacy, safety, and mechanisms of Autologous Micrografting Technology for androgenetic alopecia, reporting significant short-term improvements in hair density and thickness.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

In this case report, a 41-year-old male developed myasthenia gravis following alopecia areata, with prednisolone and tacrolimus improving his symptoms; a literature review identified 29 reported cases of this comorbidity, with some showing additional autoimmune diseases, suggesting a shared immunological mechanism.

The Ewha Medical Journal is now in PubMed, has an AI article editor, and offers Korean reporting guidelines.

This article discusses baricitinib, a JAK1 and JAK2 inhibitor, as an approved and promising treatment for alopecia areata but reports no new clinical results.

HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.

This review highlights current and future AI applications in hair restoration and diagnosis of hair disorders, including automated systems for hair detection and self-diagnosis, emphasizing the need for experts to understand their benefits and limitations.

This review examines various pharmacological options for managing alopecia areata, highlighting the effectiveness of corticosteroids for mild to moderate cases and promising results from JAK inhibitors like baricitinib for more severe forms, with additional benefits from minoxidil and potential from other treatments.

This study suggests that while adding baricitinib to formularies may increase costs for government hospitals, it could expand treatment options and potentially improve outcomes for patients with AA. Further analyses are recommended to assess its cost-effectiveness in terms of outcomes improvement.

This study reports a unique case of identical twins experiencing alopecia areata at the same time, suggesting potential environmental triggers for this polygenic autoimmune condition.

This study analyzed survey responses from 800 alopecia areata patients and found a possible genetic association with increased insulin-dependent diabetes mellitus in relatives but not in the patients themselves.

This study found that intramuscular anti-IFN-γ significantly stabilized and promoted hair regrowth in alopecia areata patients with patchy, progressive hair loss, whereas those with total baldness showed more limited improvement.

This study discusses the development of AI in dermatology and cosmetology, noting its use in skin cancer diagnosis and personalized cosmetics, while highlighting uncertainties about whether recent advancements represent significant medical progress or are influenced by marketing strategies.

In this study, PA-011 extract was reported to promote hair growth and alleviate alopecia areata symptoms in mice by reducing skin inflammation and modulating skin microbiota.

In laboratory experiments, this study found that the topical prodrug SCD-153, a derivative of 4-methyl itaconate, reduced inflammation-related gene expression and induced significant hair growth in mice, suggesting it as a promising treatment candidate for alopecia areata.

This study observed that amelanotic melanocytes from human hair follicles appeared morphologically immature, suggesting they might not transfer melanosomes into keratinocytes.

This study suggests that scalp rolling could be a promising and affordable adjuvant treatment for alopecia areata, potentially promoting hair regrowth by enhancing the effects of topical medications and inducing collagen.

This study suggests that a newly discovered protein, AMY117, found in Alzheimer's disease brain lesions may be crucial in the disease's development and progression.

In this study, US-based experts reached a consensus on treating adults with severe alopecia areata, recommending oral Janus kinase inhibitors as the primary long-term therapy, while also suggesting supplemental treatments like minoxidil and corticosteroids, with a call for more research on specific patient subpopulations.

This study analyzed gene expression data to identify key genes involved in severe forms of alopecia areata, discovering four immune monitoring genes (LGR5, SHISA2, HOXC13, S100A3) with potential for early diagnosis and better understanding of the disease's biological mechanisms.

This study found that the JAK3/TEC kinase inhibitor ritlecitinib was effective and well tolerated in patients aged 12 and older with alopecia areata, providing a potential systemic treatment option for this condition, especially in cases of significant psychosocial impact.

This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.

This study found that topical adenosine significantly increased the ratio of thick hairs and contributed to global improvement in Japanese men with androgenetic alopecia compared to niacinamide, with no observed adverse events.